SPERO THERAP.INC. DL-,001

Spero Therapeutics entered into a $105 million licensing and financing agreement with subsidiaries of Healthcare Royalty (KKR). HCRx will receive a portion of milestone and royalty payments from GSK’s Utebzi sales and will receive quarterly principal and interest payments from those receipts; after full repayment Spero will retain 35% of subsequent GSK payments. The funds will be used primarily to advance the phase-2 immunology candidate SP001, and Spero’s cash runway has been extended into the second half of 2029. The announcement pushed Spero’s stock down about 12% in premarket trading. » More on de.investing.com

Spero Therapeutics agreed a non‑recourse royalty financing of $105 million with Healthcare Royalty (KKR), assigning part of future milestone and license payments from Utebzi sales. The funds will finance development of SP001, a monoclonal anti‑CD40L antibody intended for Phase 2; simultaneously Spero signed an exclusive licensing agreement with Innovent for SP001. Healthcare Royalty will receive quarterly principal and interest payments from GSK payments, and after repayment Spero will retain 35% of subsequent GSK payments; Spero thereby extends its cash runway into the second half of 2029 and reports a current ratio of 10.5. » More on de.investing.com

Shares of Spero Therapeutics climbed 16% after the FDA approved Utebzi, an oral carbapenem developed with GSK to treat complicated urinary tract infections in adults with limited oral options. Utebzi is the first oral carbapenem approved in the U.S.; the approval is based on the Phase III PIVOT-PO study, which showed noninferiority to intravenous imipenem‑cilastatin. The drug is expected to be available in the U.S. by the end of 2026; development was partially supported by BARDA. » More on de.investing.com